Abstracts

Development framework harvest (PMID:24303304) ‘Links’. Genomic data is stored in the cloud-enabled VIVA platform and accessed through cross-platform integration and standardization algorithms for comparison and reporting. Data sets include source identification, data validation, and standardization of molecular and phenotypic data (2017), a web-enabled data mart that provides phenotype-genotype query/exploration, along with raw and processed data file downloads to authorized investigators (Harvard identified tools for filtering and analysis of genomics data) at the level of a phenotype, sample, gene, and variant (VIVA, 2017–2018), and uploaded digitized slides (Aperio, 2019); The IDPG/DMG repository stores abstracted datasets for >1020 patients with DIPG/DMG, of whom 366 have tumor tissue available through biopsy and/or autopsy, and centrally re-reviewed and digitized specimens from 124 patients. The Repository contains >5000 radiology studies from >700 patients, with >550 patients centrally reviewed, and genomics data from 80 patients. Currently 27 IDPG/DMG approved projects utilize these datasets. The DIPG/DMG Registry constructed a cross-platform and integration structure to promote highly collaborative, international, hypothesis-driven research. Broadening collaboration among investigators for hypothesis-driven research studies will lead to better classification and more effective treatment of patients with DIPG and DMG.

EPID-16. INTEGRATION OF EHR AND CANCER REGISTRY DATA TO CONSTRUCT A PEDIATRIC-NEURO-ONCOLOGY SURVIVORSHIP COHORT AND IMPROVE LONG-TERM FOLLOW-UP CARE

David Novell1, Claire Howell, Kevin Offinger, Daniel Landi, and Kristin Schroeder

Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark, USA

BACKGROUND: Pediatric neuro-oncology (PNO) survivors suffer long-term physical and neurocognitive morbidity. Comprehensive care addressing late effects of brain tumors and treatment in these patients is important. Clinical guidelines offer a framework for evaluating late effects, yet lack of extended follow-up is a significant barrier. The electronic health record (EHR) allows novel and impactful opportunities to construct, maintain, and leverage survivorship cohorts for health care delivery and as a platform for research. METHODS: This survivorship cohort includes all PNO cases ≤18-years-old reported to the state-mandated cancer registry by our institution. Data mining of the EHR for exposures, demographic, and clinical data identified patients with late effects. Follow-up analysis to identify the specific survivorship cohort. Thirty patients died with an overall mortality of 9.3%. Two-hundred-and-sixteen patients were seen in PNO clinic, of which 18.5% (n=40) did not receive extended follow-up. Patients without extended follow-up were an average of 3.3 years older (p<0.01); however, there was no statistical difference in preferred language (p=0.97) or race/ethnicity (p=0.41). CONCLUSION: Integration of EHR and cancer registry data represents a feasible, timely, and novel approach to construct a PNO survivorship cohort to identify and re-engage patients without extended follow-up. Future applications include analysis of exposures and complications during therapy on late effects outcomes.

EPID-17. A SINGLE INSTITUTE EXPERIENCE IN THE REGISTRATION STUDY OF PEDIATRIC SOLID TUMOR IN JAPAN CHILDREN’S CANCER GROUP

Keiko Funakawa1, Yotsuba Minehara4, and Yoshiki Arakawa1; 1Kyoto University Hospital Cancer Center, Kyoto City, Kyoto Pref., Japan, 2Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto City, Kyoto Pref, Japan, 3Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto City, Kyoto Pref., Japan

A larger scale prospective registration study has been conducted nationwide in Japan since 2011, called as “registration study in pediatric solid tumor”, in Japan Children’s Cancer Group (JCCG). In this study, clinical data and surgical specimen are collected into the National Center for Child Health. Kyoto University Hospital has participated in this study since IRB approval in 2011. We reviewed our registered patients to the registration study and assessed the current status. 40 patients with pediatric brain tumors participated in this study from 2011 to 2020. There were 13 intracranial germ cell tumors, 9 medulloblastomas, 6 gliomas in 4 diffuse midline gliomas, 4 pilocytic astrocytoma, and 4 other types of tumors. The informed consent was obtained from 36 patients by pediatricians and 3 patients by neurosurgeons. Twenty-five surgical specimens were collected for central review. The reasons of no surgical specimens were nonsurgical management in 6 patients and no enough FFPE sample in 3 patients. There was no discrepancy between central review and institutional diagnosis. The status of clinical data entry was complete in 13 patients and incomplete in 9 patients.

These registration data including pathological diagnosis, molecular diagnosis, treatment, clinical information in patients with pediatric brain tumor are very important to realize current status. To conduct this study certainly, the collaboration among pediatrician, neurosurgeon, and supporting staff should be needed in collecting specimens and clinical data.

EPI-18. TRENDS IN INCIDENCE AND SURVIVAL OF MALIGNANT PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS IN THE NETHERLANDS

Rasoul Hoogendoorn1, Jasper van der Lugt1, Danniis van Vaarderen, 1Eelko Hoving1, Leonotten Kremer1,2, Pieter Wesseling1,3, and Henriek Herinckx1,2

1Prinses Maxima Centrum for Pediatric Oncology, Utrecht, Netherlands, 2Amsterdam University Medical Centers/Emma Children’s Hospital/AMC, Amsterdam, Netherlands, 3Amsterdam University Medical Centers/VUMc, Amsterdam, Netherlands, 4Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands

BACKGROUND: Variation in survival of pediatric central nervous system (CNS) tumors is large between countries. Within Europe, the Netherlands had one of the worst reported survival rates of malignant CNS (mCNS) tumors during 2000–2007. METHODS: Using the Netherlands Cancer Registry, we evaluated trends in incidence and survival of pediatric mCNS tumors (behavior IS, 5th digit in the morphology code) diagnosed between 1985–2017. RESULTS: A total of 839 newly-diagnosed pediatric patients <18 years were registered between 1990–2017. Incidence of mCNS tumors remained stable (average incidence rate, 21.6 per million person-years). However, an increased incidence of malignant gliomas, NOS was found (Estimated Annual Percentage Change (EAPC) 11.6% p<0.001). This appears to be related to a registration shift between 1990–1999 and 2000–2009 as brainstem tumors increased (+25%, n=79) for astrocytomas and other gliomas but decreased (-31%, n=32) for unspecified intracranial and intraspinal neoplasms. Overall, 5-year observed survival (5Y-OS) of mCNS tumors increased from 51% in 1990–1999 to 61% in 2010–2017 (P-for-trend<0.001). This increase was not constant over time, as 5Y-OS for the period 2000–2009 was 47%. The only significant decrease in survival was found for malignant intracranial and intraspinal astrocytomas and other gliomas with a 5Y-OS of 56% in 1990–1999 decreasing to 48% in 2010–2017 (P-for-trend<0.001). CONCLUSION: Between 1990–2017 incidence of mCNS tumors in the Netherlands remained stable and survival increased. However, a decrease in survival for malignant intracranial and intraspinal astrocytomas and other gliomas was partially explained by the registration shift of brainstem tumors. The impact of this shift on survival for all mCNS tumors is subject to further research.

ETMR-01. TREATMENT OUTCOME OF TWO CASES WITH HIGH-GRADING NEUROEPITHELIAL TUMOR WITH BCOR ALTERATION

Ines Kristensen1, Louise Lindholm Hansen1, Torben Stamm Mikkelsen1, Louise Tram Henriksen1, Benedatc Parn Uldh2, Gesch Vond Oettingen1, Soen Corinum1, and Yasmin Khan-Ramsah1

1Pediatric Oncology, Aarhus University Hospital, Aarhus, Denmark, 2Aarhus University Hospital, Aarhus, Denmark

INTRODUCTION: High grade neuroepithelial tumor with BCOR exon 13 internal tandem duplication (HGNET-BCOR) is a recently described tumor entity of the central nervous system (CNS) with a distinct methylation profile and characteristic genetic alteration. We report the outcome of two cases after 1st line multimodality therapy. MATERIAL AND METHOD: A 7-year old girl with a ventricular tumour and a 6 year old boy with a tumour in the occipital region with infiltration of the transverse and sigmoid sinuses were both diagnosed based on histology and methylation with HGNET-BCOR. No spinal or liquor dissemination were found at diagnosis in both cases. Treatment consisted of radical resection of the tumour and chemotherapy, radiotherapy and concomitant vincristine and adjuvant Cisplatin, Lomustine and Vincristine. RESULTS: The girl developed a local recurrence at the primary tumour site 18 months after diagnosis. Reoperation showed the same histology. Start of 2nd line chemotherapy with Temozolomid and Irinotecan is being discussed. The boy with sinus infiltration developed seven months after diagnosis multifocal lesions in his brain and lung and bone metastasis. Biopsy of a liver lesion showed HGNET-BCOR. He was treated with Temozolomid, Irinotecan and died nine months after diagnosis. CONCLUSION: We report two cases with failure after 1st line treatment for HGNET-BCOR. To our knowledge HGNET-BCOR with development of hematological disease dissemination is a rare finding.